Johnson & Johnson Reports Positive Results for Nipocalimab in Lupus Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: PRnewswire
- Clinical Trial Success: Johnson & Johnson's nipocalimab met its primary endpoint in the JASMINE study by significantly reducing disease activity in systemic lupus erythematosus (SLE) patients at 24 weeks, indicating its potential in treating moderate-to-severe SLE.
- Sustained Long-term Efficacy: The study results demonstrated that disease activity continued to decrease through 52 weeks, particularly in approximately 80% of autoantibody-positive patients, showing a significantly greater response compared to the placebo group, suggesting broad applicability of the drug.
- Good Safety Profile: Nipocalimab exhibited a safety profile consistent with previous studies, with no new safety signals identified; common adverse reactions included nasopharyngitis, headache, and urinary tract infections, indicating its safety in clinical use.
- FDA Fast Track Designation: Nipocalimab has received Fast Track Designation from the U.S. FDA for SLE, further advancing its potential market application and expected to provide new treatment options for SLE patients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 223.510
Low
190.00
Averages
218.50
High
240.00
Current: 223.510
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nipocalimab Achieves Breakthrough in Lupus Study
- Clinical Trial Success: Nipocalimab met its primary endpoint in the JASMINE study, significantly reducing disease activity in systemic lupus erythematosus (SLE) patients at 24 weeks, with a 53.5% SLE Responder Index 4 (SRI-4) response rate in the 15 mg/kg group compared to 46.7% in the placebo group, indicating its potential therapeutic effect.
- Long-term Efficacy: At 52 weeks, 53.6% of patients receiving nipocalimab achieved an SRI-4 response, suggesting strong prospects for long-term disease control, potentially providing sustained management of SLE for patients.
- Efficacy in Targeted Population: The study revealed higher SRI-4 response rates in autoantibody-positive patients at 58.2%, compared to 36.1% in the placebo group, indicating nipocalimab's potential to change treatment strategies for specific patient populations.
- Good Safety Profile: Nipocalimab's safety profile was consistent with previous studies, with no new safety signals identified; common adverse reactions included nasopharyngitis, headache, and urinary tract infections, suggesting its acceptability in clinical use.
See More
Johnson & Johnson's Nipocalimab Shows Promising Results in Lupus Study
- Clinical Trial Success: Johnson & Johnson's experimental drug nipocalimab met its primary endpoint in a Phase 2 study for moderate-to-severe systemic lupus erythematosus, significantly reducing disease activity at 24 weeks and maintaining efficacy for one year, indicating its potential in treating this condition.
- Better Response in Antibody-Positive Patients: Results showed that participants who tested positive for lupus-associated autoantibodies, representing about 80% of the population, had a significantly better response to nipocalimab compared to placebo plus background medication, further validating the drug's effectiveness and targeting.
- Sustained Efficacy: In the 15 mg/kg group, the significant reduction in systemic lupus erythematosus disease activity was not only evident at the 24-week primary endpoint but also sustained through Week 52, suggesting the drug's long-term therapeutic potential.
- Phase 3 Study Recruitment Ongoing: Johnson & Johnson is currently recruiting patients with systemic lupus erythematosus for the Phase 3 study of nipocalimab, aiming to further validate its efficacy and advance the drug's market application to meet the urgent treatment needs of patients.
See More
Johnson & Johnson's New Drug Study Shows Significant Efficacy
- Clinical Response Improvement: In the DAHLIAS study, participants with elevated antibody levels treated with nipocalimab achieved a clinical response rate of 62.5%, significantly higher than the overall rate of 51.9%, indicating the drug's potential in severe cases.
- Biomarker Insights: New analyses reveal the role of pathogenic IgG autoantibodies in disease activity, supporting nipocalimab's effectiveness as a targeted treatment, which could enhance patients' quality of life.
- Research Significance: The study results will be presented at the 2026 EULAR Congress, emphasizing the need for deeper understanding and new treatment options for Sjögren's disease, potentially driving future clinical applications.
- Market Potential: Given that Sjögren's disease affects approximately 4 million people globally and currently lacks effective treatments, the successful development of nipocalimab could open new market opportunities for Johnson & Johnson in the autoimmune disease sector.
See More
Johnson & Johnson Reports Positive Results for Nipocalimab in Lupus Study
- Clinical Trial Success: Johnson & Johnson's nipocalimab met its primary endpoint in the JASMINE study by significantly reducing disease activity in systemic lupus erythematosus (SLE) patients at 24 weeks, indicating its potential in treating moderate-to-severe SLE.
- Sustained Long-term Efficacy: The study results demonstrated that disease activity continued to decrease through 52 weeks, particularly in approximately 80% of autoantibody-positive patients, showing a significantly greater response compared to the placebo group, suggesting broad applicability of the drug.
- Good Safety Profile: Nipocalimab exhibited a safety profile consistent with previous studies, with no new safety signals identified; common adverse reactions included nasopharyngitis, headache, and urinary tract infections, indicating its safety in clinical use.
- FDA Fast Track Designation: Nipocalimab has received Fast Track Designation from the U.S. FDA for SLE, further advancing its potential market application and expected to provide new treatment options for SLE patients.
See More
Jim Cramer Highlights Undervalued Stocks Amid Tech Fatigue
- Investment Opportunity Identification: Jim Cramer highlights that as tech stocks lose momentum, investors should focus on undervalued stocks, particularly JPMorgan Chase, which is trading at a forward P/E of about 13, down from 15 at the start of the year, indicating its attractiveness.
- Healthcare Sector Potential: Cramer believes Johnson & Johnson may present a more appealing investment option due to its drug pipeline and growing medical technology business, although he remains positive on Eli Lilly as well.
- Consumer Goods Stability: Cramer favors Kimberly-Clark for its strong brand portfolio and attractive dividend yield, with the planned merger with Kenvue expected to further enhance its market position.
- Restaurant Sector Rebound: Cramer points to McDonald's and Yum! Brands, arguing that the tech sector's popularity has undervalued these stocks, particularly with Yum! Brands considering the sale of Pizza Hut, which sweetens its investment case.
See More
Investors Should Consider Out-of-Favor Sectors
- Investment Opportunity Identification: CNBC's Jim Cramer suggests that investors should consider out-of-favor sectors, particularly as tech stocks may retreat, highlighting potential beneficiaries like JPMorgan, Johnson & Johnson, Kimberly-Clark, McDonald's, Yum! Brands, and Kraft Heinz.
- Financial Sector Potential: Cramer points out that JPMorgan's forward P/E ratio is around 13 times, down from 15 at the beginning of the year, and despite a 7% decline year-to-date, its value as a quality franchise remains attractive, indicating investment opportunities amid economic slowdown concerns.
- Healthcare Sector Outlook: Cramer believes Johnson & Johnson's drug pipeline and growing medical technology business present significant growth potential, suggesting it may offer a more attractive investment opportunity than Eli Lilly, while advising investors to buy slowly due to market uncertainties.
- Consumer Goods and Restaurant Sector: Cramer highlights Kimberly-Clark's household brand portfolio and appealing dividend yield, along with the investment value of McDonald's and Yum! Brands, particularly with Yum! potentially selling Pizza Hut, which enhances its investment appeal.
See More
Nipocalimab Achieves Breakthrough in Lupus Study
- Clinical Trial Success: Nipocalimab met its primary endpoint in the JASMINE study, significantly reducing disease activity in systemic lupus erythematosus (SLE) patients at 24 weeks, with a 53.5% SLE Responder Index 4 (SRI-4) response rate in the 15 mg/kg group compared to 46.7% in the placebo group, indicating its potential therapeutic effect.
- Long-term Efficacy: At 52 weeks, 53.6% of patients receiving nipocalimab achieved an SRI-4 response, suggesting strong prospects for long-term disease control, potentially providing sustained management of SLE for patients.
- Efficacy in Targeted Population: The study revealed higher SRI-4 response rates in autoantibody-positive patients at 58.2%, compared to 36.1% in the placebo group, indicating nipocalimab's potential to change treatment strategies for specific patient populations.
- Good Safety Profile: Nipocalimab's safety profile was consistent with previous studies, with no new safety signals identified; common adverse reactions included nasopharyngitis, headache, and urinary tract infections, suggesting its acceptability in clinical use.
See More
Johnson & Johnson's Nipocalimab Shows Promising Results in Lupus Study
- Clinical Trial Success: Johnson & Johnson's experimental drug nipocalimab met its primary endpoint in a Phase 2 study for moderate-to-severe systemic lupus erythematosus, significantly reducing disease activity at 24 weeks and maintaining efficacy for one year, indicating its potential in treating this condition.
- Better Response in Antibody-Positive Patients: Results showed that participants who tested positive for lupus-associated autoantibodies, representing about 80% of the population, had a significantly better response to nipocalimab compared to placebo plus background medication, further validating the drug's effectiveness and targeting.
- Sustained Efficacy: In the 15 mg/kg group, the significant reduction in systemic lupus erythematosus disease activity was not only evident at the 24-week primary endpoint but also sustained through Week 52, suggesting the drug's long-term therapeutic potential.
- Phase 3 Study Recruitment Ongoing: Johnson & Johnson is currently recruiting patients with systemic lupus erythematosus for the Phase 3 study of nipocalimab, aiming to further validate its efficacy and advance the drug's market application to meet the urgent treatment needs of patients.
See More
Johnson & Johnson's New Drug Study Shows Significant Efficacy
- Clinical Response Improvement: In the DAHLIAS study, participants with elevated antibody levels treated with nipocalimab achieved a clinical response rate of 62.5%, significantly higher than the overall rate of 51.9%, indicating the drug's potential in severe cases.
- Biomarker Insights: New analyses reveal the role of pathogenic IgG autoantibodies in disease activity, supporting nipocalimab's effectiveness as a targeted treatment, which could enhance patients' quality of life.
- Research Significance: The study results will be presented at the 2026 EULAR Congress, emphasizing the need for deeper understanding and new treatment options for Sjögren's disease, potentially driving future clinical applications.
- Market Potential: Given that Sjögren's disease affects approximately 4 million people globally and currently lacks effective treatments, the successful development of nipocalimab could open new market opportunities for Johnson & Johnson in the autoimmune disease sector.
See More
Johnson & Johnson Reports Positive Results for Nipocalimab in Lupus Study
- Clinical Trial Success: Johnson & Johnson's nipocalimab met its primary endpoint in the JASMINE study by significantly reducing disease activity in systemic lupus erythematosus (SLE) patients at 24 weeks, indicating its potential in treating moderate-to-severe SLE.
- Sustained Long-term Efficacy: The study results demonstrated that disease activity continued to decrease through 52 weeks, particularly in approximately 80% of autoantibody-positive patients, showing a significantly greater response compared to the placebo group, suggesting broad applicability of the drug.
- Good Safety Profile: Nipocalimab exhibited a safety profile consistent with previous studies, with no new safety signals identified; common adverse reactions included nasopharyngitis, headache, and urinary tract infections, indicating its safety in clinical use.
- FDA Fast Track Designation: Nipocalimab has received Fast Track Designation from the U.S. FDA for SLE, further advancing its potential market application and expected to provide new treatment options for SLE patients.
See More
Jim Cramer Highlights Undervalued Stocks Amid Tech Fatigue
- Investment Opportunity Identification: Jim Cramer highlights that as tech stocks lose momentum, investors should focus on undervalued stocks, particularly JPMorgan Chase, which is trading at a forward P/E of about 13, down from 15 at the start of the year, indicating its attractiveness.
- Healthcare Sector Potential: Cramer believes Johnson & Johnson may present a more appealing investment option due to its drug pipeline and growing medical technology business, although he remains positive on Eli Lilly as well.
- Consumer Goods Stability: Cramer favors Kimberly-Clark for its strong brand portfolio and attractive dividend yield, with the planned merger with Kenvue expected to further enhance its market position.
- Restaurant Sector Rebound: Cramer points to McDonald's and Yum! Brands, arguing that the tech sector's popularity has undervalued these stocks, particularly with Yum! Brands considering the sale of Pizza Hut, which sweetens its investment case.
See More
Investors Should Consider Out-of-Favor Sectors
- Investment Opportunity Identification: CNBC's Jim Cramer suggests that investors should consider out-of-favor sectors, particularly as tech stocks may retreat, highlighting potential beneficiaries like JPMorgan, Johnson & Johnson, Kimberly-Clark, McDonald's, Yum! Brands, and Kraft Heinz.
- Financial Sector Potential: Cramer points out that JPMorgan's forward P/E ratio is around 13 times, down from 15 at the beginning of the year, and despite a 7% decline year-to-date, its value as a quality franchise remains attractive, indicating investment opportunities amid economic slowdown concerns.
- Healthcare Sector Outlook: Cramer believes Johnson & Johnson's drug pipeline and growing medical technology business present significant growth potential, suggesting it may offer a more attractive investment opportunity than Eli Lilly, while advising investors to buy slowly due to market uncertainties.
- Consumer Goods and Restaurant Sector: Cramer highlights Kimberly-Clark's household brand portfolio and appealing dividend yield, along with the investment value of McDonald's and Yum! Brands, particularly with Yum! potentially selling Pizza Hut, which enhances its investment appeal.
See More
